Edwards Lifesciences
EW
$85.73
-2.40%
Edwards Lifesciences designs, manufactures, and markets medical devices for advanced structural heart disease, including surgical tissue heart valves and transcatheter aortic, mitral, and tricuspid valve technologies. As the market leader in transcatheter aortic valve replacement (TAVR), the company derives about 60% of its sales outside the US and competes with Medtronic and Boston Scientific. The current investor narrative centers on a potential Medicare coverage expansion for TAVR, which could broaden patient access and drive growth, alongside a recent beat-and-raise quarter that highlighted robust demand for its heart valve therapies.…
EW
Edwards Lifesciences
$85.73
Related headlines
EW 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $99.00 and implied upside of +15.5% versus the current price.
Average Target
$99.00
0 analysts
Implied Upside
+15.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
Edwards Lifesciences is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating 1.71 on a 1-5 scale where 1 is Strong Buy). The average price target is $98.80, implying 15.2% upside from the current price of $85.73. The distribution shows a bullish lean, with no sell ratings among recent institutional ratings; firms like Mizuho, RBC Capital, and Citigroup maintain Outperform or Buy ratings. The target price range spans from $84.00 (low) to $110.00 (high). The high target of $110 assumes successful TAVR expansion and margin improvement, while the low target of $84 reflects risks from competitive pressures or slower adoption. Recent ratings have been stable, with no downgrades in the past three months, indicating analyst conviction. The spread between low and high ($26) is moderate, suggesting reasonable uncertainty but not extreme divergence in views.
Drowning in data?
Find the real signal!
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences presents a compelling growth story with accelerating revenue, expanding margins, and a strong balance sheet, supported by a potential Medicare catalyst. However, the stock trades at a significant premium to peers (trailing P/E 46.3x vs. industry 22x), and recent price action shows underperformance. The bull case is stronger given the fundamental momentum and analyst consensus, but the key tension is whether the high valuation can be justified by sustained earnings growth. If revenue growth decelerates or margins compress, the premium could unwind, leading to downside.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 16.7% YoY to $1.649B, accelerating from 10.8% in Q4 2025, driven by strong TAVR adoption and potential Medicare expansion.
- High and Expanding Profit Margins: Net margin improved to 23.1% in Q1 2026 from 5.8% in Q4 2025, with gross margin at 78.2% and operating margin at 31.2%, well above industry averages.
- Analyst Consensus Buy with Upside: 25 analysts rate EW a Buy with an average target of $98.80, implying 15.2% upside from $85.73; no sell ratings and a high target of $110.
- Fortress Balance Sheet: Debt-to-equity is only 0.068, current ratio is 3.72, and TTM free cash flow is $1.09B, providing ample liquidity and financial flexibility.
Bearish
- Premium Valuation vs. Peers: Trailing P/E of 46.3x is more than double the industry average of ~22x, implying high growth expectations that may not materialize.
- Near-Term Price Weakness: Stock is down 2.4% on the last trading day and has underperformed the S&P 500 over the past year (12.5% vs. 18.4%), with a 1-month relative strength of -1.4%.
- Dependence on TAVR Growth: Transcatheter Heart Valves segment generated $1.197B in Q1 2026, representing 73% of total revenue, making the company highly exposed to TAVR market dynamics.
- Negative Free Cash Flow in Q1: Q1 2026 free cash flow was -$21.1M due to working capital changes, which could raise concerns if sustained, despite strong TTM FCF of $1.09B.
EW Technical Analysis
Edwards Lifesciences is in a sustained uptrend, with the stock up 12.5% over the past year, outperforming the broader market's 18.4% gain. The current price of $85.73 sits at 38% of its 52-week range ($72.30–$96.29), indicating it is closer to the low end after a pullback from recent highs. This positioning suggests the stock may be offering a value entry point if the uptrend resumes, but also reflects near-term selling pressure. Short-term momentum is mixed: the 1-month change is -1.1%, while the 3-month change is +5.9%, showing a deceleration from the longer-term trend. The 1-month relative strength vs. SPY is -1.4%, indicating underperformance, but the 3-month relative strength is +1.2%, suggesting the stock has recently regained some ground. The divergence between the 1-month and 3-month trends could signal a temporary pullback within a broader uptrend rather than a reversal. The 52-week high of $96.29 acts as key resistance, while the 52-week low of $72.30 provides support. A breakout above $96.29 would signal renewed bullish momentum, while a breakdown below $72.30 could indicate a trend reversal. With a beta of 0.86, the stock is less volatile than the market, meaning it may offer downside protection during market declines but could lag during rallies.
Beta
0.85
0.85x market volatility
Max Drawdown
-12.7%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+12.5%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -1.1% | -0.5% |
| 3m | +5.9% | +4.9% |
| 6m | +1.6% | +9.7% |
| 1y | +12.5% | +18.4% |
| ytd | +0.5% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Revenue is growing strongly, with Q1 2026 revenue of $1.649 billion, up 16.7% year-over-year, accelerating from the 10.8% growth in Q4 2025. The trailing twelve-month revenue trend shows consistent expansion from $1.386 billion in Q4 2024 to $1.649 billion in Q1 2026. The Transcatheter Heart Valves segment generated $1.197 billion in Q1 2026, while Transcatheter Mitral and Tricuspid Therapies contributed $175 million, indicating that TAVR remains the primary growth driver. This accelerating growth supports the investment case for continued market share gains and TAVR adoption. The company is highly profitable, with Q1 2026 net income of $380.7 million and a net margin of 23.1%, up from 5.8% in Q4 2025. Gross margin remains stable at 78.2%, while operating margin improved to 31.2% in Q1 2026 from 23.6% in Q4 2025, reflecting operating leverage. These margins are well above industry averages for medical devices, indicating strong pricing power and cost control. Edwards has a fortress balance sheet with a debt-to-equity ratio of just 0.068 and a current ratio of 3.72, indicating ample liquidity. Free cash flow (TTM) is $1.09 billion, though Q1 2026 free cash flow was negative $21.1 million due to working capital changes. The company generates sufficient cash to fund operations and growth without external financing, and its low debt levels minimize financial risk.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 46.3x, while the forward P/E is 25.5x, implying the market expects significant earnings growth over the next year. The gap between trailing and forward P/E suggests that earnings are expected to nearly double, which aligns with the recent acceleration in revenue and margin expansion. Compared to the industry average P/E of 22.0x (estimated), Edwards trades at a 110% premium on a trailing basis, reflecting its dominant market position and superior growth. The forward P/E of 25.5x is still above the industry average but more reasonable, indicating that the premium is partially justified by expected earnings growth. Historically, Edwards' trailing P/E has ranged from 28.5x (Q4 2024) to 133.2x (Q4 2025), with the current 46.3x near the middle of that range. The current P/E is below the peak of 133.2x seen in Q4 2025 (when earnings were temporarily depressed), suggesting the stock is not excessively overvalued relative to its own history. However, it is above the 28.5x level from Q4 2024, indicating that the market is pricing in improved profitability.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Edwards' high valuation (trailing P/E 46.3x) leaves little room for error; any earnings miss could trigger multiple compression. While debt is minimal (D/E 0.068), the negative free cash flow in Q1 2026 (-$21.1M) warrants monitoring, though TTM FCF remains strong at $1.09B. Revenue concentration in TAVR (73% of sales) exposes the company to procedure volume fluctuations and competitive dynamics. Market & Competitive Risks: The stock's beta of 0.86 suggests lower market correlation, but its premium valuation makes it vulnerable to sector rotation out of growth. Competitors Medtronic and Boston Scientific are investing heavily in TAVR, which could erode Edwards' market share. The recent Medicare proposal is a positive catalyst, but any delay or unfavorable policy change would be a headwind. Worst-Case Scenario: A combination of slower TAVR adoption, competitive losses, and a broad market downturn could drive the stock to its 52-week low of $72.30, representing a 15.7% decline from the current price of $85.73. In a severe scenario, if earnings disappoint and the P/E contracts to 30x, the stock could fall to ~$60, a 30% loss.
